Featured Research

from universities, journals, and other organizations

Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-refractory RA Patients

Date:
June 13, 2008
Source:
European League Against Rheumatism
Summary:
New data show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.

New data presented June 13 at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.

The ATTEST (Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA) trial compared abatacept (~10mg/kg), a selective T cell co-stimulation modulator, with infliximab (3mg/kg), a monoclonal antibody, plus methotrexate (as per each patient's usual dosage, mean dose 16.3-16.6mg) in 431 methotrexate-refractory patients, in a randomised, double-blind, placebo-controlled, 12-month study. Data analyses evaluated the proportion of patients who achieved a 20% improvement in symptoms (as defined by the American College of Rheumatology scale as an ACR20 response) at six months and went on to either improve, maintain or lose this score at twelve months. A similar analysis was conducted in relation to Low Disease Activity Score (LDAS) (DAS28 [CRP] d3.2).

ACR Response

Of those patients who achieved an ACR20 response at six months (32 abatacept [ABA] and 27 infliximab [IFX] patients), over a quarter of ABA and IFX patients went on to achieve a 50% improvement (ACR50) at one year (ABA 28.1%, IFX 29.6%). These ACR20 scores were maintained to one year in more ABA than INF patients (95% confidence interval, CI) with over half ABA patients sustained (ABA 59.4%, IFX 44.4%). Furthermore, half as many ABA patients lost their ACR20 score between six months and one year compared to IFX patients (ABA 12.5%, IFX 25.9%).

Low Disease Activity Score

In the LDAS analysis, it was shown that 24 ABA and 23 IFX patients achieved LDAS (but not remission) at six months. Of these patients, over a third ABA (41.7% [22.8, 63.1]) and a quarter IFX patients (28% [12.9, 49.6]) achieved remission at one year. A similar number of ABA (12.5% [3.3, 33.5]) and IFX patients (16% [5.3, 36.9]) retained LDAS to one year, whilst fewer ABA patients (45.8% [26.2, 66.9]) than IFX patients (56% [35.3, 75.0]) lost their LDAS score between six months and one year.

Lead researcher Dr Michael Schiff, of the University of Colorado, USA, commented: "Since RA is a chronic disease, long term treatment efficacy is crucial. Clinical rheumatologists and patients alike need to know the options for maintaining or even increasing treatment responses over time, especially with the growing problem of RA patients becoming refractory, or resistant, to existing treatments. Our study offers significant promise in showing that, where treatment with methotrexate as monotherapy is inadequate, both abatacept and infliximab provide an increasing magnitude of response in measures of RA disease activity, with abatacept yielding slightly higher results across some key ACR and LDAS scores."


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-refractory RA Patients." ScienceDaily. ScienceDaily, 13 June 2008. <www.sciencedaily.com/releases/2008/06/080613105857.htm>.
European League Against Rheumatism. (2008, June 13). Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-refractory RA Patients. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2008/06/080613105857.htm
European League Against Rheumatism. "Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-refractory RA Patients." ScienceDaily. www.sciencedaily.com/releases/2008/06/080613105857.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins